These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 1281074)
21. [Welfare as the goal of the analgesic pharmacotherapy accompanying biological treatment in patients with rheumatoid arthritis and ankylosing spondylitis]. Tomasiewicz B; Hurkacz M; Jarzibowski J; Wiela-Hojeńska A Pol Merkur Lekarski; 2014 Nov; 37(221):274-9. PubMed ID: 25546988 [TBL] [Abstract][Full Text] [Related]
28. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281 [TBL] [Abstract][Full Text] [Related]
29. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. Tam HW; Yeo KJ; Leong PY; Chen CH; Li YC; Ma CM; Wang YH; Chiou JY; Wei JC Int J Rheum Dis; 2017 Mar; 20(3):363-370. PubMed ID: 27943609 [TBL] [Abstract][Full Text] [Related]
30. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Litalien C; Jacqz-Aigrain E Paediatr Drugs; 2001; 3(11):817-58. PubMed ID: 11735667 [TBL] [Abstract][Full Text] [Related]
31. A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Marzo-Ortega H; Green MJ; Keenan AM; Wakefield RJ; Proudman S; Emery P Arthritis Rheum; 2007 Feb; 57(1):154-60. PubMed ID: 17266089 [TBL] [Abstract][Full Text] [Related]
32. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Hanauer SB; Stathopoulos G Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590 [TBL] [Abstract][Full Text] [Related]
33. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis. Chitul A; Voiosu AM; Marinescu M; Caraiola S; Nicolau A; Badea GC; Pârvu MI; Ionescu RA; Mateescu BR; Voiosu MR; Băicuş CR; Rimbaş M Rom J Intern Med; 2017 Mar; 55(1):44-52. PubMed ID: 28103201 [TBL] [Abstract][Full Text] [Related]
34. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. Gorman JD; Sack KE; Davis JC N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408 [TBL] [Abstract][Full Text] [Related]
35. Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. Braun J; Baraliakos X; Westhoff T Semin Arthritis Rheum; 2020 Apr; 50(2):285-288. PubMed ID: 31439354 [TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs. Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519 [TBL] [Abstract][Full Text] [Related]
37. Ankylosing spondylitis and current disease-controlling agents: do they work? Maksymowych WP; Breban M; Braun J Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):619-30. PubMed ID: 12406430 [TBL] [Abstract][Full Text] [Related]
38. Spondyloarthritides in females. Gran JT; Ostensen M Baillieres Clin Rheumatol; 1998 Nov; 12(4):695-715. PubMed ID: 9928503 [TBL] [Abstract][Full Text] [Related]
39. Use of simple analgesics in the treatment of ankylosing spondylitis. Pal B Br J Rheumatol; 1987 Jun; 26(3):207-9. PubMed ID: 2437989 [TBL] [Abstract][Full Text] [Related]
40. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. Hammoudeh M; Zack DJ; Li W; Stewart VM; Koenig AS J Int Med Res; 2013 Aug; 41(4):1150-9. PubMed ID: 23803306 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]